Quantcast

East and Central Asia

Basilea Pharmaceutica in license agreement with Chinese drugmaker

Basilea Pharmaceutica has entered into a license agreement with Shenzhen China Resources Gosun Pharmaceutical Co., Ltd. (CR Gosun) for Basilea’s antibiotic Zevtera (ceftobiprole) in China, Hong Kong and Macao (the Territory).

Posted in Asia, news, Regions | Tagged , , | Leave a comment

Novo Nordisk’s diabetes drug in China

China Food and Drug Administration (CFDA) has approved Novo Nordisk’s Tresiba (insulin degludec) for the treatment of diabetes in China.

Posted in Approval, Asia, news, Regions | Tagged , , , | Leave a comment

Mylan to sell tuberculosis drug in two highest-burden countries for the disease

Otsuka Pharmaceutical and Mylan N.V. have entered into a license agreement between their respective subsidiaries, Otsuka Novel Products GmbH (ONPG) and Mylan Pharmaceuticals Private Limited (Mylan), to commercialize delamanid for the treatment of adults with pulmonary multidrug-resistant tuberculosis (MDR-TB) in low- and middle-income countries.

Posted in Africa, Asia, news, Regions | Tagged , , , , | Leave a comment

SillaJen, Lee’s Pharmaceutical cleared for third phase testing cancer treatment Pexa-Vec

SillaJen and Lee’s Pharmaceutical Holdings have said that they’ve gotten the approval from the China Food and Drug Administration (CFDA) to get a Phase 3 clinical trial for advanced liver cancer using its oncolytic immunotherapy called Pexa-Vec, the PHOCUS study.

Posted in Approval, Asia, news, Regions | Tagged , , | Leave a comment

Celgene and BeiGene join to fight cancer

Celgene Corporation and BeiGene have entered into a strategic collaboration to develop and commercialize BeiGene’s investigational anti-programmed cell death protein 1

Posted in Asia, Europe, news, studies | Tagged , , | Leave a comment

Ipsen’s third phase trial of Somatuline lead to Japan’s clearance for new indication, certain tumors

Ipsen’s partner Teijin Group healtcare’s Pharma Limited, has received approval from the Japanese Ministry of Health, Labour and Welfare for Ipsen’s subcutaneous drug Somatuline (lanreotide) for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP NET).

Posted in Approval, Asia, news, Regions | Tagged , , , | Leave a comment

Breast cancer patients testing Enzychem’s cheaper Mosedipimod, hopes for FDA’s approval

Announcing the phase 2 testing on Monday, the company said that the multicenter study of EC-18 (Mosedipimod), the world’s first oral medicine candidate to prevent and treat Chemotherapy-Induced Neutropenia (CIN), will begin dosing its first patient in the Asan Medical Center of Seoul, Korea. Enzychem also said it hopes to have EC-18 be approved by the FDA.

Posted in Approval, Asia, news, Regions | Tagged , , , | Leave a comment

Sanovas expands in China, $75 million in capitalization

Sanovas, Inc., a Life Science technology company will establish a venture capital fund and Innovation Center at the Suzhou Institute of Nanotechnology and NanoBionics (SINANO) at the Chinese Academy of Sciences to advance the company’s innovations and sales in China.

Posted in Approval, Asia, news | Tagged , | Leave a comment

Grünenthal buys AstraZeneca’s migraines drug

AstraZeneca has signed an agreement with Grünenthal for the global rights to Zomig (zolmitriptan), the drug indicated for the acute treatment of migraines and cluster headaches, outside Japan.

Posted in Asia, news, North America, Regions | Tagged , , | Leave a comment

Asia to be drug delivery technology market fastest-growing region

Drug delivery technology market grows from $1,179.20 billion to $1,669.40 billion at a CAGR of 7.2% from 2016-2021. Oral drug delivery segment is expected to account for the largest share while hospitals segment is expected to account for the largest share of the market and Asia is expected to be fastest-growing region.

Posted in Approval, Asia, Europe, news, North America, Regions | Tagged , | Leave a comment